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Summary 
Background: Breast cancer is the most common form of
cancer in women. It arises from multiple genetic changes in
oncogenes and tumor suppressor genes. Among so far
studied oncogenes relatively few, including epdermal
growth factor receptor (EGFR), cyclinD1 (CCND1)and c-
myc, have been found to play an important role in progres-
sion of this type of human malignancy. The aim of this study
was to examine the prognostic potential of CCND1, c-myc
and EGFR amplification and their possible cooperation in
breast carcinogenesis.
Methods: Copy number analyses of CCND1 and c-myc
genes were done by TaqMan based quantitative real time
PCR. Am pli fication status of EGFR was determined by dif-
ferential PCR.
Kratak sadr`aj
Uvod: Kancer dojke je naj~e{}i tip maligniteta koji se javljaja
kod `ena. Tumori dojke nastaju kao rezultat akumulacije
geneti~kih promena kako u onkogenima tako i u tumor
supresorskim genima. Me|u mnogim onkogenima ~ija je
uloga u genezi tumora dojke ispitivana do danas, samo se
neki smatraju zna~ajnim za razvi}e ovih karcinoma. U tu se
grupu svakako ubrajaju receptor za epidermalni factor rasta
(EGFR), c-myc i ciklinD1 (CCND1). Cilj rada je bio utvrditi
prognosti~ki zna~aj amplifikacije CCND1, c-myc i EGFR
onkogena u razvicu tumora dojke kao i eventualne me|usob-
ne koalteracije ovih gena.
Metode: Amplifikacioni status CCND1 i c-myc gena odre|en
je kvantitativnim PCR-om u realnom vremenu, a amplifikaci oni
status EGFR onkogena je definisan diferencijalnim PCR-om.
List of Abbrevations: EGFR, epidermal growth factor recep-
tor; HER, human epidermal growth factor receptor; QUART,
quadrantectomy; SMIR, subcutaneous mastectomy; PCR,
polymerase chain reaction; HT, hormone therapy; RT, radio-
therapy; CHT, chemiotherapy.
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Introduction
Breast cancer is the most common form of can-
cer in women. It comprises 22% of all cancers (1) and
is second only to lung cancer as a cause of cancer
related death in women (2). It is a heterogeneous dis-
ease arising from multiple genetic changes in onco-
genes and tumour suppressor genes with pivotal roles
in the control of cell proliferation, differentiation and
death. Alterations of these genes lead to clonal
expansion with subsequent acquisition of invasive and
metastatic phenotypes. 
Numerous oncogenes have been characterized
in human cancers, but relatively few have been found
to play an important role in promotion and progres-
sion of breast cancer. Among them are epidermal
growth factor receptor (EGFR), cyclin D1 and c-myc. 
EGFR (also known as HER1) is a member of the
human epidermal growth factor receptor (HER) fam-
ily of transmembrane receptor tyrosine kinases that is
linked to growth control, cell adhesion, mobility and
apoptosis (3). Its role in breast tumors is complicated
by the fact that its function may vary according to
important clinical features like estrogen receptor (ER)
and HER2 status (4). Namely, high expression of
EGFR has been reported to be associated with low
expression of ER (5).
Cyclin D1 is the product of the CCND1 gene
and plays the central role in the regulation of progres-
sion from the G1 to the S phase of the cell cycle
through the formation of active enzyme complexes
with cyclin-dependent kinases Cdk4 and Cdk6 (6).
Consequently, deregulation of cyclin D1 gene expres-
sion or function contributes to loss of normal cell
cycle control during carcinogenesis. Strong evidence
implicates cyclin D1 amplification and overexpression
as a driving force in human breast cancer (7).
c-myc protein is a transcription factor which par-
ticipates in most aspects of cellular function, includ-
ing replication, growth, metabolism, differentiation,
and apoptosis (8). Most, if not all, types of human
malignancy have been reported to have amplification
and/or overexpression of c-myc oncogene.
Thus, amplification and overexpression of these
oncogenes and oncogene products are the major
mechanisms through which these genes participate in
carcinogenesis. A drawback of many studies of onco-
genes in human breast cancer is that usually only one
oncogene was evaluated. Based on a series of unse-
lected cases, in the present study we aimed to exam-
ine the possible prognostic potential of the amplifi -
cation of CCND1, c-myc and EGFR oncogenes.
More over, we aimed to determine whether these
onco genes cooperate in breast carcinogenesis.
Further more we studied whether adjuvant therapies
such as chemotherapy and endocrine treatment or no
treatment at all had any impact on survival among
oncogene amplified breast cancer patients.
Material and Methods
Patients
This prospective study comprised of 49 primary
breast cancer tissue samples. 21 patients underwent
modified radical mastectomy, 19 underwent quadran-
tectomy (QUART) and 9 underwent subcutaneous
mastectomy (SMIR) at the Institute of Oncology and
Radiology of Serbia. All relevant clinical parameters
(age, tumor size, lymphonodal status, disease free
Results: Amplification of CCND1, c-myc and EGFR onco-
gene has been found in 20.4%, 26.5% and 26.5% of breast
cancer cases, respectively. Analysis showed that amplification
of CCND1 oncogene was significantly associated with the
stage II of disease while amplification of EGFR gene was sig-
nificantly associated with overexpression of HER-2/neu. Tu -
mour stage and expression of HER-2/neu appeared to be
significant predictors of patient’s outcome. Stage I patients
lived significantly longer then stage III patients (p=0.04)
while patients with HER-2/neu overexpression had worse
prognoses and lived significantly shorter (p=0.001). Finally,
survival of patients who underwent hormone therapy only
was significantly longer (p=0.001) then survival of the rest
of patients.
Conclusions: Amplification of CCND1 or EGFR oncogene is
associated with the progression of breast cancer and bad
prognosis. No co-ordination in amplification of CCND1, c-
myc and EGFR oncogenes were established in this cohort of
breast cancer patients.
Keywords: breast cancer; oncogenes; cycline D1, c-myc,
EGFR
Rezultati: Amplifikacija CCND1 gena detektovana je kod
20.4%, a c-myc i EGFR onkogena kod 26.5% ispitanih uzo-
raka. Analize su pokazale da je amplifikacija CCND1 onko-
gena statisti~ki zna~ajno povezana sa stadijumom II tumora
dojke kao i da amplifikacija EGFR-a zna~ajno korelira sa
pove }anom ekspresijom HER2/neu. Analize klini~kih i histo -
patolo{kih parametara su jasno pokazale da stadijum tumo-
ra i nivo ekspresije HER2/neu gena predstavljaju zna~ajne
pokazatelje daljeg toka bolesti, odnosno sudbine pacijenta.
Utvr|eno je da pacijentkinje sa tumorima dojke stadijuma I
`ive zna~ajno du`e od onih sa tumorom stadijuma III (p=
0.04) kao i da pacijentkinje sa HER2/neu pozitivnim statu-
som imaju goru prognozu i `ive zna~ajno kra}e (p=0.001).
Na kraju, studija je pokazala da pacijentkinje podvrgnute
samo hormonskoj terapiji imaju najbolju prognozu i `ive
zna~ajno du`e od ostalih (p=0.001).
Zaklju~ak: Amplifikacija CCND1 i EGFR onkogena je po -
vezana sa lo{om prognozom i progresijom karcinoma dojke.
U ispitivanom tumorskom uzorku nisu detektovane nikakve
koalteracije CCND1, c-myc i EGFR onkogena.
Klju~ne re~i: tumori dojke, onkogeni, ciklin D1, c-myc,
EGFR
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survival, overall survival) were retrieved from patients’
medical records.
Collected tumor specimens and corresponding
normal tissue were formalin-fixed, paraffin-embed-
ded and hematoxylin-eosin (HE) stained. Histological
type and grade of each carcinoma sample were deter-
mined after hematoxylin-eosin staining. The carcino-
mas were graded (I – III) according to Scarff-Bloom-
Richardson scoring system (9).
For each obtained tumor sample written consent
and approval were acquired according to the ethical
standards laid down in the1964 Declaration of Hel -
sinki, the International Ethical Guidelines for Bio -
medical Research Involving Human Subjects (CIOMS),
Geneva 1993, and the Guidelines for Good Clinical
Practice CPMP/ICH/135/95), September 1997.
Immunohistochemistry
Labelled streptavidin-biotin-LSAB+ method to -
gether with immunoperoxidase was used according to
recommended procedure for commercial primary
monoclonal mouse antibody: Anti-Human ERa clone
(1:50; Clone 1D5; Dako) and Anti-Human PR clone
(1:50; Clone PgR 636; Dako), as well as for policlon-
al rabbit antibody Anti-Human c-erbB2/HER2
Oncoprotein (1:300; Dako) with Dako LSABTM+/
HRP kit (K0679). Slices were contrasted with Mayer
hematoxylin.
The evaluation of steroid receptros (ER, PR) was
based on the scoring system which included percent-
age of stained malignant nuclei (0-5) and their intensi-
ty of staining (0–3); positive (high expression) cases
were with score ≥4 while negative (low expression)
cases were with score <4 (10). HER2 status was deter-
mined using DAKO scoring system and HER2 positive
status was defined if IHC score was 2+/3+ (11).
Copy number analysis by quantitative real time
PCR
Genomic DNA was extracted from 49 fresh fro -
zen tumor and corresponding normal tissue samples
according to the standard phenol/chloroform extrac-
tion procedure described by Sambrook and colleagues
(12). The quality of the extracted DNA was verified by
agarose gel electrophoresis and the concentrations
were assessed spectrophotometrically. Isolated DNA
was stored at +4 °C until further analyses.
Copy number analyses of CCND1 and c-myc
genes were done by quantitative real time PCR using
TaqMan based assays. Assays included forward and
reverse primers for c-myc and CCND1 oncogenes as
well as highly specific 6-Fam-TAMRA labeled probes
for them. Primers and probe for CCND1 gene were as
follows: F 5’-GGACAACGGGCGGATAGAG-3’; R 5’-
CACAGTCATCCCAGGGTTTAACA-3’; Probe 6-FAM-
5’-CAGCCTTGTTGTTTACGGCCTCTTTGAG-3’-
TAMRA. For the analysis of c-myc gene, the following
primers and probe were used: F 5’-GGACGACGA-
GACCTTCATCAA-3’; R 5’-CCAGCTTCTCTGAGAC-
GAGCTT-3’; TaqMan Probe 6-FAM-5’-AGAAGC-
CGCTCCACATACAGTCCTGG-3‘-TAMRA.
RNase-P was used as the internal control, refer-
ence gene (accession # 4316831, Applied Bio -
systems).
Each sample was prepared in duplicate, in total
reaction volume of 20 mL, with primers /probe ratio
3:1 (0.1 mmol/L probe : 0.3 mmol/L primers), 1x
TaqMan Master Mix and 150ng of tested DNA. Each
reaction contained normal DNA controls. Control
samples were used as calibrators. PCR reactions were
carried out in the ABI Prism 7500 Sequence
Detection System at 50 °C for 2 minutes, 95 °C for 10
minutes, followed by 40 cycles at 95 °C for 15 sec-
onds, and 60 °C for 1 minute. The experimental
threshold was calculated based on the mean baseline
fluorescence signal from cycles 3 to 15 plus 10 stan-
dard deviations. A mean value of each Ct duplicate
was used for further calculation. Each run included a
no-template control, as well. The obtained results
were analyzed by RQ Study Add ON software for
7500 v 1.3 SDS instrument with a confidence level of
95% (p<0.05).
Differential PCR
Amplification status of EGFR oncogene was de -
termined by differential PCR (D-PCR) that engaged
two pairs of primers, one for the target gene (EGFR)
and the other for the reference gene (b-actin). The
primer sequences were as follows: EGFR_F 5’-AGC-
CATGCCCGCATTAGC TC-3’ and EGFR_R 5’-AACC-
CTTCAACGTAAGGAAA-3’ for EGFR, and ACTB_F
5’-CTCTTTTCTTTCCCGATAGGT-3’ and ACTB_R
5’-CTCCAGCTTCTCGTAGGGTC-3’ for the ACTB.
D-PCR was performed in the total reaction volume of
25 mL with 150 ng of DNA, 1× PCR buffer (50
mmol/L KCl, 10 mmol/L Tris–HCl, pH 8.3, 0.01%
gelatin), 1.5 mmol/L MgCl, 0.2 mmol/L each dNTP,
1 mmol/L each of four primers, 1U Taq Poly merase.
Thermal cycling included thirty repeats of denatura-
tion at 95 °C/1 minute, annealing at 58 °C/1 minute
and extension at 72 °C/1 minute, with initial denatu-
ration (95 °C/10 minutes) before and final extension
(72 °C/10 minutes) after the repeating temperature
steps. Generated PCR products were applied to 9%
polyacrylamide gel for electrophoresis, stained with
silver-nitrate, photographed and analyzed by Image -
Quant 5.2 by comparing the median pixel intensity in
a given/selected area of two bands (EGFR and ACTB)
in the same lane (sample). When median pixel inten-
sity of EGFR band was equal or higher then 25% of
median pixel intensity of ACTB, it was interpreted as
gene amplification.
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Statistical analysis
Significant differences between the data sets
were determined by STATISTICA 6.0 software
(StatSoft, Inc., Tulsa, USA). The correlations between
clinicopathological parameters and amplification of c-
myc, CCND1 and EGFR genes were evaluated using
Fisher exact test. Survival analyses were performed
using Kaplan & Meier product-limit method. The log
rank test was used to asses the significance of the dif-
ference between pairs of survival probabilities. Overall
survival was calculated from the day after surgery to
the last follow-up examination or death of the patient.
Statistical differences were considered significant
when p was < 0.05 (*).
Results
Patient cohort and treatment
We examined breast cancer specimens from 38
postmenopausal and 11 premenopausal women for
the amplification status of c-myc, CCND1 and EGFR
oncogenes. In total of 49 patients, 27 patients had
breast carcinomas with histology of invasive ductal
carcinoma, while 22 were invasive lobular carcino-
mas. Patients’ characteristics are summarized in Table
I. Among clinical and histopathological characteris-
tics, stage and HER-2/neu expression were significant
predictors of patient’s outcome (Figures 1A and 1B).
Namely, stage I patients lived significantly longer then
stage III patients (p=0.04) while patients with HER-
2/neu overexpression had worse prognoses and lived
significantly shorter (p=0.001). Most of the samples
were steroid receptor (ER and/or PR) positive (96%)
but, nevertheless, patients were on different regimens
of treatment: 5 of them were on hormone therapy
(HT), 8 on combined hormone and radiotherapy
(HT+RT), 4 on combined hormone and chemiother-
apy (HT+CHT), 17 on combined hormone, chemio-
and radiotherapy (HT+CHT+RT) and 15 on other
therapeutic protocols (CHT only, RT only, combined
CHT and RT). Kaplan-Meier survival curves were gen-
erated to evaluate the effects of these treatment re -
gimens on survival. The survival of patients who
underwent hormone therapy only was significantly
longer (p=0.001) then survival of the rest of patients
(Figure 1C). 
Amplification of c-myc, CCND1 and EGFR 
oncogenes
We determined amplification status of CCND1
and c-myc oncogenes by Quantitative Real Time
PCR. Our results revealed that 10 out of 49 samples
(20.4%) possessed three to 14-fold amplification of
CCND1 oncogene. c-myc gene was amplified three
to 10-folds in 13/49 breast cancer samples (26.5%).
Further analysis by Fisher exact test showed that
amplification of CCND1 oncogene was significantly
associated with the stage II of breast cancer patients
(Table II). On the contrary, amplification of c-myc
gene did not show correlation with tumour stage
(Table II) or any other clinical or pathohistological
characteristics of patients (data not shown) including
breast cancer subtype, ER or HER2/neu status. 
Amplification of EGFR oncogene was assessed
by differential PCR and we found that it was amplified
in 13 patients (26.5%). Interestingly, amplification of
EGFR gene was significantly associated with overex-
pression of HER-2/neu (Table II). In other words,
EGFR expressing tumours were more likely to over-
express HER-2/neu. Association with any other cli -
nical or pathohistological characteristic was not
obtained. 
In order to reveal possible association among
three studied oncogenes, we further analyzed
whether there were co-alterations between any of
them. Our results showed that there was no co-oper-
ation among CCND1, c-myc and EGFR gene alter-
ations. Namely, CCND1 and c-myc were co-amplified
in four samples (8%), as were CCND1 and EGFR
while c-myc and EGFR were co-altered in only two
samples (4%). All three of them were amplified in just
one breast cancer sample.
Further, we analyzed possible association
between each oncogene alteration and survival and
did not find anything of significance (Figure 2).
Finally, neither of them had any significant influence
on response to any applied therapeutic protocol.
Table I Patients’ characteristics.
Age in years (mean)                     32 – 82 (61)
Follow-up in months (mean)          36 – 110 (31)
Estrogen receptor status
positive
negative
HER-2/neu status
positive
negative
Stage*
I
II
III
Grade
g 1
g 2
g 3 
Lymph node metastasis
Yes
No
47
2
19
30
12
20
12
0
44
5
27
22
TOTAL 49
* – unavailable data for 5 patients
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Figure 1 Kaplan–Meier survival curves. (A) Impact of tumor
stage on patients’ survival. Patients with stage I tumors lived
significantly longer compared to stage III (p=0.04); (B)
Impact of HER2/neu on patients’ survival. Patients with pos-
itive status of HER2/neu receptor lived significantly shorter
(p=0.001); (C) Impact of therapy on patients’ survival.
Patients receiving hormone therapy lived significantly longer
compared to all other groups (p=0.001).
Figure 2 Impact of oncogenes amplification on patients’sur-
vival. (A) Patients without amplification of CCND1 had ten-
dency for better survival; (B) Amplification of c-myc seems to
have no impact on patients’ survival (C) Patients without
EGFR amplification had tendency for better survival.
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Discussion
Gene amplification is an important mechanism
of oncogene activation and is crucial for the develop-
ment and progression of cancer. In the present study
we used quantitative real time PCR and differential
PCR to study gene copy number alterations of
CCND1, c-myc and EGFR oncogenes in a cohort of
49 primary breast cancer patients. 
CCND1 oncogene was amplified in 20.4% of
analyzed breast cancer samples which is consistent
with previously reported frequencies of 13%–20%.
Quantification results, which revealed that amplifica-
tion of CCND1 was three to 14-fold, are consistent
with the same reports (7, 13). Interestingly, amplifica-
tion of CCND1 gene was significantly associated with
the progression of breast cancer, both of ductal and
lobular subtypes. Specifically, it was associated with
the stage II of the disease. It is important to empha-
size that cyclin D1 is always strongly overexpressed
when amplified (14–16). Contrary to our findings,
immunohistochemical studies of preneoplastic lesions
demonstrated that overexpression of cyclin D1 had
been already apparent in hyperplasia and increased
with increasing malignancy (17). On the other hand,
in situ hybridisation studies suggest that cyclin D1
overexpression occurs at the transition from in situ to
invasive carcinoma (18). Our results imply that ampli-
fication of CCND1 oncogene could be the marker of
the progression to stage II of the disease. In addition,
studies on primary breast cancers indicate that over-
expression of cyclin D1 was confined to specific phe-
notypes, implying different roles in different subtypes
of the disease. Lobular carcinoma appears to univer-
sally overexpress cyclin D1 (19), while overexpression
in ductal carcinoma is confined almost exclusively to
estrogen receptor positive cases (20). We have not
observed any difference in CCND1 amplification
between lobular and ductal breast carcinomas but we
are limited in discussing this issue since 96% of our
samples are ER positive. 
The need for cooperativity with other oncogenic
hits is entirely expected for an authentic human onco-
gene (7), which was the reason why we analyzed the
amplification of c-myc and EGFR in the same cohort
of samples. c-myc gene was amplified in 26.5% of
analyzed samples, slightly above reported frequencies
(21, 22), but did not show any co-ordination with
CCND1 amplification. Barnes and Gillette (23) have
also shown that CCND1 gene is amplified in cases
were c-myc is not. Although this reciprocal amplifica-
tion seems to be consistent with the observation that
c-myc represses the transcription of cyclin D1 (24),
direct evidence is still lacking for a reciprocal relation-
ship between the expression of c-myc and that of
cyclin D1.
The role that epidermal growth factor receptor
plays in breast cancer has been a subject of intensive
study and controversy. Some retrospective immuno-
histochemical studies have indicated that EGFR over-
expression in primary tumors is an indicator of poor
prognosis (25), whereas other similar studies have
failed to establish such a link (26). Collectively, these
studies suggest that EGFR is expressed in 18–35% of
breast cancers (27). Our study revealed that EGFR
oncogene was amplified in 26.5% of examined sam-
ples. No co-alteration with c-myc and CCND1 was
observed. However, amplification of EGFR gene
showed significant association with the expression of
HER-2/neu. The largest and the most comprehensive
study analyzing EGFR expression in breast cancer
patients showed that EGFR expression was positively
correlated with HER-2/neu overexpression, which has
been associated with bad prognosis (28). Our results
confirm this finding since Kaplan & Meier survival
analysis showed that patients with HER-2/neu overex-
pression had worse prognoses and lived significantly
shorter.
Parameter TotalaNP
CCND1 c-myc EGFR
NP %           p NP %           p NP %           p
Total
Stage b
I
II
III
HER2/neu status
positive
negative
49
12
20
12
19
30
10
0
6
3
6
4
20.4
0
30.0
25.0
31.6
13.4
p1 0.04c
p2 0.55
p3 0.11
0.12
13
4
6
3
4
9
26.5
33.3
30.0
25.0
21.1
30.0
p1 0.57
p2   0.55
p3 0.50
13
2
8
3
8
5
26.5
16.7
40.0
25.0
42.1
16.7
p1 0.16
p2 0.32
p3 0.50
0.05c
Table II Association between amplified oncogenes, stage and HER2/neu status.
a Number of patients; b unavailable data for 5 patients c Bold indicates statistically significant values; p1 – statistical significance
between stages I and II; p2 – statistical significancee between stages II and III; p3 – statistical significance between stages I and
III
Finally, the most promising therapy in this
patient’s cohort was endocrine (hormone) therapy.
We looked for an oncogene signature in the back-
ground and found that samples of patients who
underwent endocrine therapy did not have amplifica-
tions of CCND1 and EGFR oncogenes. This was not
a surprise since the overexpressions of both, CCND1
and EGFR, have been associated with the resistance
to hormone therapy and chemotherapy in a number
of studies (29, 30). However, the therapy groups ana-
lyzed in the present study are small, and therefore we
recommend careful interpretation of the findings.
In conclusion, amplification of CCND1 or EGFR
oncogenes is associated with the progression of
breast cancer and bad prognosis. No co-ordination in
amplification of CCND1, c-myc and EGFR oncogenes
was established in this cohort of breast cancer
patients.
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